Currently out of the existing stock ratings of Steve Chesney, 17 are a BUY (45.95%), 7 are a SELL (18.92%), 13 are a HOLD (35.14%).

Steve Chesney

Work Performance Price Targets & Ratings Chart

Analyst Steve Chesney, currently employed at REDBURN, carries an average stock price target met ratio of 67.08% that have a potential upside of 27.55% achieved within 498 days.

Steve Chesney’s has documented 76 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BMY, Bristol-Myers Squibb Company at 05-Feb-2024.

Wall Street Analyst Steve Chesney

Analyst best performing recommendations are on CELG (CELGENE).
The best stock recommendation documented was for CELG (CELGENE) at 12/18/2015. The price target of $122 was fulfilled within 5 days with a profit of $11.86 (10.77%) receiving and performance score of 21.54.

Average potential price target upside

of $100.59 (22.69%) on IDXX (IDEXX LABORATORIES).
of $50.63 (17.26%) on BIIB (BIOGEN).
of $27.1 (32.99%) on ABBV (ABBVIE).

BIIB Biogen ABBV AbbVie AMGN Amgen BMY Bristol-Myers Squibb Company JNJ Johnson & Johnson MRK Merck mpany IDXX IDEXX Laboratories PFE Pfizer ZTS Zoetis CELG Celgene

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Ami Fadia (NEEDHAM)